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GLM and multistate models, is that it adjusts for the two main sources of bias. 
Estimates obtained through this method are within the range defined by the other 
two approaches. We propose that this new method provides more accurate esti-
mates of the actual economic burden of HAIs.
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Objectives: It is well-accepted that data pre-processing and the creation of 
matching cohorts may provide a more balanced assessment in real world evidence 
analysis. The objective of this study is to show that proper selection of a propensity 
score matching (PSM) algorithm can significantly enhance the sensitivity of treat-
ment cost comparison for rare diseases using claims databases. MethOds: Five 
years of retrospective inpatient commercial insurance claims data from Truven 
MarketScan™ were used to compare the six-month drug cost of ‘Drug X’ to ‘Drug 
Y’ for a rare disease, with Drug Y being the market leader. Within this study, three 
different types of PSM techniques were used (naïve matching, logit and recursive 
partitioning) to determine the impact of matching algorithms on the sensitivity of 
final comparison. A 2:1 matching ratio was used to take advantage of much larger 
patient pool for Drug Y. Results: Without PSM, the difference in cost of the two 
treatments was not statistically significant, although these results show that the 
spending for Drug X patients is approximately $220 less than Drug Y users over a 
6 month period. In the naïve matching method, the drug cost of treatment X was 
$234 lower than treatment Y, although the observed difference was not statistically 
significant. Using the logit regression algorithm, it was found that the mean cost 
of Drug X was approximately $368 lower than Drug Y (p= 0.028). Lastly, with non-
linear recursive partitioning PSM, the treatment cost of Drug X was $351 lower than 
Drug Y (p= 0.045). cOnclusiOns: The use of PSM in studies can help to remove 
potential confounders and produce unbiased results. Model-based PSM outperforms 
naïve matching in terms of enhancing analysis sensitivity. The careful selection of 
a matching algorithm can play a pivotal role in economic investigations for rare 
diseases using real world evidence.
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Objectives: Non-alcoholic Steatohepatitis (NASH) is the hepatic manifestation of 
metabolic syndrome with an increasing prevalence globally. Although there are no 
currently approved treatments, NASH therapeutic research and development efforts 
are ongoing, targeting multiple aspects of the complex disease pathways. Halting or 
reversing inflammation and progressive liver fibrosis are core endpoints to evaluate 
therapeutic efficacy. The choice of diagnostic tool may have implications on the 
length of study and related costs. MethOds: We sought to evaluate current studies 
on www.clinicaltrials.gov using search term ‘NASH’, and assess efficacy outcomes, 
related length of clinical programs, and research activities in relation to epidemiol-
ogy. We included studies in our analysis that were: “Interventional, Phase 2, 3, or 4, 
known status”, from Europe or North America, and NASH fibrosis and/or inflam-
mation, not related to viral infection. We estimated current development costs, 
and applied alternative biomarker composite endpoints, to assess potential cost 
and time savings. Results: As of January 2014, there are 199 NASH studies posted 
to clinicaltrials.gov, of which 54 studies met our criteria. Thirty seven of those 54 
studies use histology (liver biopsy) as the primary endpoint at a mean timepoint of 
58.5 weeks, compared to 18.1 weeks when non-invasive diagnostic methods (serum 
markers of inflammation and fibrosis, imaging) are used (p< 0.0001). cOnclusiOns: 
Our data show that utilization of non-invasive markers as primary efficacy end-
points can allow for clinical trials of considerably shorter duration which may have 
an impact on cost-efficiency of clinical development programs for NASH. Further 
study is required to expand upon these findings as well as validate biomarkers for 
acceptable use in registrational trials.
ReseaRch on Methods – databases & Management Methods
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Objectives: Patients with comorbid alcohol use disorders (AUD) and substance 
use disorders (SUD) may be identified in administrative claims data using a range 
of codes (eg ICD-9 303-305), but it is not clear this yields a homogenous group. 
The objective of this study was to characterize patients with AUD/SUD claims to 
better understand the resulting comorbidity measures. MethOds: Patients with 
≥ 1 claim indicative of AUD/SUD between 2005-2012 were identified in the Truven 
Health MarketScan® Commercial and Medicare Research Databases. Continuous 
enrollment 6 months before and 12 months after the earliest AUD/SUD claim was 
required. Patients were analyzed overall, then stratified by earliest drug of abuse 
(alcohol, amphetamines, cannabis, cocaine, hallucinogens, sedatives, opioids) for 
bivariate comparison of patient characteristics, cost and utilization. Results: The 
sample included 476,628 patients; most (73%) with an AUD diagnosis. Overall, the 
sample was mean age 39 and 63% male. Total post-index costs were mean $17,481 
and median $7,332. Other cost measures were similarly skewed. Less than half 
(43%) had a second AUD/SUD claim ≥ 30 days post-index. The sedative cohort had 
Consideration of the causes of variability and appropriate statistical analyses to 
generate unbiased estimators and reliable confidence intervals remains a chal-
lenge for these studies.
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Objectives: Neurodegenerative diseases (NDs) refer to a group of diseases that 
affect brain cells. Alzheimer disease (AD), Parkinson disease (PD), Amyotrophique 
Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) are the most prevalent NDs. NDs 
cause a substantial economic burden worldwide and indirect costs are an important 
component of total costs. This study aims to review relevant papers to characterize 
the different components of indirect costs and to identify the weight of indirect 
costs on total costs in different NDs. MethOds: A systematic bibliographic search 
was performed on an international medical literature database (MEDLINE). All stud-
ies which assessed the social economic burden and indirect costs of different NDs 
were selected. Indirect costs were characterized into several types (i.e. sick leave, 
presenteeism, early retirement, premature death, reduction in working hours, infor-
mal care time) and into several valuation (i.e. Human Capital Approach, Friction Cost 
Method, Willingness To Pay). Results: 44 studies met our criteria. Depending on 
studies, the percentage of indirect costs on total costs varies from 1% to 68% in PD, 
from 2% to 89% in AD, from 24% to 59% in ALS and from 29% to 78% in MS. The main 
indirect costs component was early retirement in PD, ALS and MS. This component 
varies from 61% to 95% of indirect costs in PD, from 35% to 88% in ALS and from 61% 
to 95% in MS. The main indirect costs component in AD was informal care time and 
account for almost 100% of indirect costs. Indirect costs increase with severity level 
in AD and MS, and decrease with severity level in ALS. cOnclusiOns: Components 
of indirect costs are different depending on studies and especially for AD where 
indirect costs mainly refer to informal costs which should be considered as a full 
cost category to avoid the lack of understanding.
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Objectives: In this study we explore the methodological challenges presented by 
retrospective economic analyses of vaccination programs and offer direction for 
future evaluations in the area. Post-implementation evaluation should be an impor-
tant part of assessing the success of public health programs; however relatively 
little attention has been focused on evaluating the value for money achieved by 
vaccination programs after they have been introduced. MethOds: We conducted a 
narrative review of the limited existing economic evaluation literature assessing the 
cost-effectiveness of implemented vaccination programs. We evaluated the alterna-
tive approaches to addressing the challenges that these retrospective evaluations 
present. These challenges were then contrasted and compared with those that 
prospective economic evaluations face. Results: The key challenges identified 
for retrospective economic evaluations include the estimation of: disease changes 
attributable to vaccination efforts, the hypothetical no vaccination comparator 
scenario and the full benefits likely to be achieved by implemented vaccination 
programs. We also present other important factors that may need to be considered 
such as the evolution of prices over time. cOnclusiOns: Retrospective economic 
analyses of vaccination programs are likely to become more frequent and influential 
and it is important that both the benefits and the limitations of these evaluations 
are recognised and understood. Further work needs to be done to explore how the 
practical application of alternative approaches may impact on the results of evalu-
ations in different circumstances.
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Objectives: In the current health care environment, it is critical that we obtain 
better insights into the economic burden of major complications, such as health 
care associated infections (HAIs). Commonly used methods, however, are limited 
in that they provide cost and length of stay (LOS) estimates, adjusted either for 
patients’ heterogeneity (generalized linear model (GLM)) or for the time depend-
ency of HAIs (multistate model), but don’t allow adjustment for both. We developed 
an approach that controls for both of these major confounders. MethOds: Our 
approach uses centered residuals from a GLM that account for important covariates. 
These residuals are then used in a multistate model to estimate the extra-LOS cor-
rected for the lead time. To obtain the dollar value, the extra-days were multiplied 
by the average cost of a post-infection day. We applied GLM, multistate and our 
new approach to a prospective multicenter observational study, assessing the inci-
dence of HAIs in cardiac surgery. Financial data were obtained from the University 
Health Consortium. Results: Among 4320 patients, 119 (2.7%) developed major 
infections during index hospitalization. Patients developing major infection after 
their surgery had longer and costlier hospitalizations than patients who did not (33 
days and $110,155 vs. 9 days and $31,530).The extra-cost and LOS due to HAIs were 
calculated using the three approaches. The new approach yields estimates ($34,632 
and 13 days) that are intermediate between those obtained from GLM ($37,922 and 
14 days) and multistate modeling ($29,304 and 11days). Results of simulations will 
be presented. cOnclusiOns: The advantage of our approach, which combines 
